Literature DB >> 20370990

Comparison of the usefulness of plasma levels of oxidatively modified forms of albumin in estimating kidney dysfunction in diabetic patients.

Agnieszka Piwowar1, Maria Knapik-Kordecka, Maria Warwas.   

Abstract

PURPOSE: Advanced oxidation protein products (AOPP) and ischemia-modified albumin (IMA) are forms of oxidatidatively modified albumin and have recently been investigated as indicators of oxidative stress. They are increased in different disorders, including diabetes mellitus, as a result of hyperglycaemia, oxidative stress and hypoxia. The usefulness of the plasma levels of these two parameters in estimating kidney dysfunction in type 2 diabetic patients (T2DM) was compared in this study.
METHODS: Plasma levels of AOPP and IMA were determined spectrophotometrically in 218 individuals, 153 patients with T2DM and 65 healthy people.. The urinary albumin/creatinine ratio (UACR) was used as the reference to define the stage of kidney dysfunction by the assessment of the degree of albuminuria.
RESULTS: Receiver Operating Characteristic (ROC) curve analysis, likelihood ratio (LR), and Youden's index (J) revealed that AOPP and IMA had acceptable sensitivities and specificities in individuals with different degrees of albuminuria; however, AOPP had higher values of the area under the curve (AUC: 0.934) than IMA, as well as 100% sensitivity and 77.01% specificity for distinguishing patients with micro- and macroalbuminuria.
CONCLUSIONS: Both AOPP and IMA may be helpful clinical markers for estimating kidney dysfunction, but AOPP is better able to identify diabetic patients with nephropathy. We suggest that AOPP is almost ideal for discriminating between T2DM patients with micro- and macroalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370990     DOI: 10.25011/cim.v33i2.12349

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  5 in total

1.  Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis.

Authors:  Shao-gang Ma; Yue Jin; Wei Xu; Wen Hu; Feng Bai; Xiao-juan Wu
Journal:  Endocrine       Date:  2012-03-23       Impact factor: 3.633

2.  Xanthine oxidase and uric acid as independent predictors of albuminuria in patients with diabetes mellitus type 2.

Authors:  Aleksandra Klisic; Gordana Kocic; Nebojsa Kavaric; Milovan Jovanovic; Verica Stanisic; Ana Ninic
Journal:  Clin Exp Med       Date:  2017-12-06       Impact factor: 3.984

3.  Evaluation of ischemia-modified albumin and C-reactive protein in type 2 diabetics with and without ketosis.

Authors:  Shao-Gang Ma; Yao Jin; Wen Hu; Feng Bai; Wen Xu; Wei-Nan Yu
Journal:  Biomark Insights       Date:  2012-03-14

4.  Evaluation of Ischemia-Modified Albumin, Malondialdehyde, and Advanced Oxidative Protein Products as Markers of Vascular Injury in Diabetic Nephropathy.

Authors:  Afzal Ahmad; Poornima Manjrekar; Charu Yadav; Ashish Agarwal; Rukmini Mysore Srikantiah; Anupama Hegde
Journal:  Biomark Insights       Date:  2016-05-02

5.  Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes.

Authors:  Kamel Mohammedi; Naïma Bellili-Muñoz; Fathi Driss; Ronan Roussel; Nathalie Seta; Frédéric Fumeron; Samy Hadjadj; Michel Marre; Gilberto Velho
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.